Fresenius (FRE) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
8 Jul, 2026Executive summary
Achieved strong organic revenue growth of 7% year-over-year for FY 2025, with Q4 organic revenue up 9% and EBIT up 13% at constant currency, driven by both Fresenius Kabi and Fresenius Helios.
Core EPS grew 16% in Q4 2025 and 12% for the full year, reflecting robust operating results and reduced interest expense.
Net debt/EBITDA improved to 2.7x, reflecting strong cash flow and debt reduction.
Dividend proposal of €1.05 per share, a 5% increase year-over-year, with a payout ratio of 37%.
Transformation strategy (#FutureFresenius, Rejuvenate) and operational improvements positioned the company for sustainable value creation.
Financial highlights
FY 2025 group revenue: €22,873m (+4% reported, +6% constant currency, +7% organic); Q4 revenue: €5,961m (+5% reported, +7% constant currency, +9% organic).
FY 2025 group EBIT: €2,595m (+6% constant currency); Q4 EBIT: €713m (+13% constant currency).
FY 2025 Core EPS: €2.87 (+12% constant currency); Q4 Core EPS: €0.78 (+16% constant currency).
Operating cash flow in Q4: €1,340m (+36% year-over-year); FY 2025: €2,606m.
Net debt/EBITDA at 2.7x, improved from 3.8x in FY 2022.
Outlook and guidance
FY 2026 guidance: organic revenue growth of 4–7%, constant currency Core EPS growth of 5–10%, EBIT margin ~11.5%.
Fresenius Kabi: organic revenue growth in mid- to high-single digits, EBIT margin 16.5–17.0%.
Fresenius Helios: organic revenue growth in mid-single digits, EBIT margin 10.0–10.5%.
Group EBIT margin expected around 11.5%; tax rate forecasted at 24–25%.
CapEx for 2026 guided at 5.5% of revenues, up from 4.4% last year.
Latest events from Fresenius
- Transformation and innovation in biosimilars and MedTech drive growth and margin gains.FRE
43rd Annual J.P. Morgan Healthcare Conference9 Jul 2026 - Growth driven by innovation, portfolio focus, and disciplined capital deployment across key healthcare segments.FRE
44th Annual J.P. Morgan Healthcare Conference9 Jul 2026 - 2027 targets raised: 4%-6% revenue growth, 10%-12% EBIT margin, digital and ESG focus.FRE
CMD 20249 Jul 2026 - Q3 2024 saw robust growth, margin expansion, and upgraded guidance despite headwinds.FRE
Q3 20248 Jul 2026 - Biopharma outpaces targets, aiming to double revenue and reach 20% EBIT margin by 2030.FRE
Status Update8 Jul 2026 - Strong FY 2024 growth and margin expansion set the stage for further gains in 2025.FRE
Q4 20248 Jul 2026 - Q1 2025 delivered strong growth, margin expansion, and cash flow, with guidance confirmed for 2025.FRE
Q1 202530 Jun 2026 - Strong Q1/26 growth, reduced leverage, and digital innovation drive a positive outlook.FRE
Credit presentation20 Jun 2026 - Q1 2026 saw 13% core EPS growth, margin gains, and guidance reaffirmed.FRE
Q1 20266 May 2026